

---

Thursday, November 6, 8:00–9:30 a.m. CT

Opening Plenary

---

**Opening Plenary: ASN President's Address, State-of-the-Art Lecture,  
Featured High-Impact Clinical Trials**

Hall A

*Note: Abstracts will be posted online by November 10, 2025.*

---

- 8:50 a.m. TH-OR082 **Finerenone in CKD and Type 1 Diabetes** – Hiddo J.L. Heerspink, David Cherney, Peter Rossing, Robert Lawatscheck, Janet B. McGill, on behalf of the FINE-ONE Investigators
- 9:02 a.m. TH-OR083 **ORIGIN 3: A Phase 3 Trial of Atacicept in IgAN** – Richard A. Lafayette, Sean Barbour, Robert M. Brenner, Kirk N. Campbell, Tom Doan, Necmi Eren, Jürgen Floege, Vivekanand Jha, Beom Seok Kim, Adrian Liew, Bart D. Maes, Atanu Pal, Roberto Pecoits-Filho, Richard K. Phoon, Dana V. Rizk, Hitoshi Suzuki, Vladimir Tesar, Hernan Trimarchi, Xuelian Wei, Hong Zhang, Jonathan Barratt, ORIGIN Phase 3 Trial Investigators

Friday, November 7, 10:30 a.m. – 12:30 p.m. CT

Oral Abstract Session

## High-Impact Clinical Trials - 1

Hall A

Moderators: Meg Jardine, MBBS, PhD; Akinlolu Ojo, MD, PhD, MBA, MPH, FASN

*Note: Abstracts will be posted online by November 10, 2025.*

- 
- 10:30 a.m. **FR-OR082 Protection Against Incidences of Serious Cardiovascular Events Study with Daily Fish Oil Supplementation in Patients on Dialysis (PISCES)** – [Charmaine E. Lok](#), Brenda Hemmelgarn, Louise M. Moist, Kevan Polkinghorne, George Tomlinson, Paul Y. Tam, Marcello Tonelli, for the PISCES Investigators
- 10:40 a.m. Discussant and Q&A
- 10:50 a.m. **FR-OR083 LIBERation from AcuTE Dialysis (LIBERATE-D)** – [Chi-yuan Hsu](#), Edward D. Siew, Delphine S. Tuot, Anitha Vijayan, Gonzalo Matzumura Umemoto, Bethany Birkelo, Yuenting D. Kwong, Ian E. McCoy, Hanjing Zhuo, Kathleen D. Liu, LIBERation from AcuTE Dialysis (LIBERATE-D) Investigators
- 11:05 a.m. **FR-OR084 Individual Treatment Effect Modeling for AKI Alerts: A Randomized Trial** – [Laura Aponte Becerra](#), Aditya Biswas, Yu Yamamoto, Melissa Martin, Francis P. Wilson
- 11:20 a.m. **FR-OR085 Randomized Clinical Trial in Older Adult Kidney Transplant Recipients Comparing Everolimus and Reduced-Dose Tacrolimus with Mycophenolate and Tacrolimus Immunosuppression: The OPTIMIZE Study** – [Stefan P. Berger](#), Silke de Boer, Jip Jonker, Frederike J. Bemelman, Michiel G. Betjes, Aiko P. De Vries, Luuk Hilbrands, Marc Hilhorst, Dirk R. Kuypers, Priya Vart, Arjan D. Van Zuilen, Dennis A. Hesselink, Jan-Stephan Sanders
- 11:35 a.m. **FR-OR086 Net Effects of SGLT2 Inhibitors by Diabetes Status and Albuminuria** – [Natalie Staplin](#), Alistair J. Roddick, Richard Haynes, William G. Herrington, on behalf of the SMART-Consortium
- 11:50 a.m. **FR-OR087 Tirzepatide vs. Dulaglutide Is Associated with Reduced Major Kidney Events in Patients with Type 2 Diabetes, CVD, and Very High-Risk Kidney Diseases** – [Sophia Zoungas](#), Stephen Nicholls, Debra L. Miller, Hiroshi Nishiyama, Russell J. Wiese, David A. D'Alessio
- 12:30 p.m. Adjourn

Saturday, November 8, 10:30 a.m. – 12:30 p.m. CT

Oral Abstract Session

## High-Impact Clinical Trials - 2

Hall A

Moderators: Laura M. Dember, MD, FASN; Richard Haynes, MBChB

*Note: Abstracts will be posted online by November 10, 2025.*

- 
- 10:30 a.m. **SA-OR082 Safety and Preliminary Efficacy Findings from a Phase 2A Randomized, Double-Blind, Placebo-Controlled Trial of Setanaxib in Patients with Alport Syndrome** – Daniel P. Gale, Irene Agraz Pamplona, Zainab Arslan, Rafael José Esteban de la Rosa, Matthew Hall, Karel Krejci, Enrique Morales, Roman Safranek, Vladimir Tesar, Roser Torra, Ondrej Viklicky, Carl Stefan Carlsson, Aaron Levine, Rachel Lennon
- 10:45 a.m. **SA-OR083 Efficacy and Safety of Telitacicept in Patients with IgAN: Results from Stage A of a Phase 3 Clinical Study** – Jicheng Lv, Li-Jun Liu, Wenxiang Wang, Jing Zhang, Weihong Mao, Qing Zuraw, Vlado Perkovic, Jianmin Fang, Hong Zhang
- 11:00 a.m. **SA-OR084 Beyond Clinical Response in the REGENCY Trial: The Impact of Obinutuzumab on Histologic Remission in Patients with Active Lupus Nephritis** – Brad Rovin, Valeria G. Alberton, Elsa Gonçalves Martins, Jay P. Garg, Mittermayer B. Santiago, Gustavo Aroca Martinez, Fedra C. Irazoque, Teresa M. Baczkowska, Jose Alfaro, Jorge L. Ravelo, Richard Furie, Luis F. Pinto, Eduardo Horacio Albiero, Christopher P. Larsen, Jennifer A. Pulley, Thomas Schindler, Theodore A. Omachi, William F. Pendergraft, Ana Malvar
- 11:15 a.m. **SA-OR085 Efficacy and Safety of MIL62, a Glycoengineered Type II Anti-CD20 Antibody, in Primary Membranous Nephropathy: A Phase 3, Randomized, Controlled Trial** – Zhao Cui, Min Wei, Peng Li, Rong Wang, Heng Li, Haitao Zhang, Hong L. Lin, Chen X. Lan, Ping Luo, Hua Zhou, Guangqun Xing, Guisen Li, Yuehong Li, Wei Chen, Junjun Zhang, Chen Yu, Wei Liang, Qiongqiong Yang, Hui X. Zheng, Hua Li, Yanning Zhang, Zhaohui Ni, Hui Xu, Xing Chen, Ming-Hui Zhao
- 11:30 a.m. **SA-OR086 Sibeprenlimab for the Treatment of IgAN: VISIONARY Phase 3 Interim and Prespecified Subgroup Analyses** – Vlado Perkovic, Jonathan Barratt, Richard A. Lafayette, Adrian Liew, Yusuke Suzuki, Kevin Carroll, Chee Kay Cheung, Vladimir Tesar, Hernan Trimarchi, Muh Geot Wong, Hong Zhang, Jing Xia, Cecile Fajardo, Lokesh N. Shah, Jeffrey Hafkin, Dana V. Rizk
- 11:45 a.m. **SA-OR087 Efficacy and Safety of Balcinrenone in Combination with Dapagliflozin on Albuminuria in Participants with CKD** – Hiddo J.L. Heerspink, Jose F. Cardona, Shivinder S. Jolly, Pablo E. Pergola, Erika De Sousa Amorim, Anna Eriksson, Martin Fredholm, Samvel B. Gasparyan, Nicolas J. Guzman, Judith Hartleib-Geschwindner, Yunyun Jiang, Maria Leonsson Zachrisson, Patrick B. Mark
- 12:30 p.m. Adjourn

## Late-Breaking Research Orals - 1

Grand Ballroom C

Moderators: Eugene P. Rhee, MD, FASN; Jodi M. Smith, MD, MPH

*Note: Abstracts will be posted online by November 10, 2025.*

- 
- 4:30 p.m. **TH-OR084 POINTER: A Phase 2b, Randomized, Placebo-Controlled, Double-Blind Dose-Finding Clinical Study of RMC-035 in Participants at High Risk for Kidney Injury Following Cardiac Surgery** – [Jay L. Koyner](#), Alexander Zarbock, Andrej Myjavec, Ignacio Muñoz Carvajal, Jan Burkert, Johannes Boehm, Elena Roselló-Díez, Klaus E. Matschke, Benoit de Varennes, Andreas Boening, Angel M. Candela-Toha, Tobias Agervald, Michael Reusch, POINTER Study Group
- 4:42 p.m. **TH-OR085 Albuminuria Change as a Surrogate End Point for Kidney Failure: An Updated Meta-Analysis of Randomised Controlled Trials** – [Hiddo J.L. Heerspink](#), Willem H. Collier, Tom Greene, Lesley A. Inker, CKD-EPI Clinical Trials Consortium
- 4:54 p.m. **TH-OR086 Clinical Decision Support Tool to Enhance Angiotensin-Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB) Use in Patients with CKD** – [Sankar D. Navaneethan](#), Lucile Parker Gregg, Peter Richardson, Michael A. Herrera, Glenn T. Gobbel, Sheena R. Wydermyer, Mohammed Al-Garadi, Dax Westerman, Salim S. Virani, Michael E. Matheny
- 5:06 p.m. **TH-OR087 Learning Health System Intervention to Increase SGLT2 Inhibitor Use** – [Areef Ishani](#), Daniel P. Murphy, Deborah Pestka, Adam N. Kaplan, Pearl H. Huynh, Jessica A. Rechtzigel, Shari Kjos, Lisa Marie Switzer, Brent C. Taylor, Melissa M. Atwood, Beth Polsfuss, Joseph Y. Lee
- 5:18 p.m. **TH-OR088 Extended In-Center Nocturnal vs. Conventional Daytime Dialysis: The NightLife Trial** – [James Burton](#), Katherine L. Hull, Niamh Quann, Ghazala Waheed, Laura J. Gray, the NightLife Investigators
- 5:30 p.m. **TH-OR089 Efficacy and Safety of Tegoprobart for the Prevention of Rejection in Kidney Transplantation: Results from the Phase 2 BESTOW Trial** – [Andrew B. Adams](#), Helio Tedesco-Silva, Steven Potter, Marcela Laurito, David Hovland, Marta Crespo, E. Steve Woodle, Oriol Bestard, Yulan Li, Elizabeth Thomas, Nassim Kamar, Steven Perrin, Anthony J. Demetris, Eliezer Katz, Flavio Vincenti
- 5:42 p.m. **TH-OR090 Safety and Efficacy of B Cell Maturation Antigen (BCMA)/CD70-Targeted Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Pediatric Patients with Multidrug-Resistant, Steroid-Resistant Nephrotic Syndrome** – [Hanyan Meng](#), Guoping Huang, Fei Liu, Yingzi Zhang, Xue He, Jingjing Wang, Jianhua Mao
- 6:00 p.m. Adjourn

**Late-Breaking Research Orals - 2**

Grand Ballroom C

Moderators: Keisha L. Gibson, MD, MPH, FASN; Kalani L. Raphael, MD, MS, FASN

*Note: Abstracts will be posted online by November 10, 2025.*

- 
- 4:30 p.m. **FR-OR088 Efficacy and Safety of the Oral Small-Molecule GLP-1 Receptor Agonist HRS-7535 in Patients with Diabetic Kidney Disease** – Xiaoying Du, Rong Lv, Zi Ye, Liang Peng, Yimei Xu, Xiang Lin, Lu Li
- 4:42 p.m. **FR-OR089 Mechanistic Effects of Semaglutide on Kidney Disease in Type 2 Diabetes: The REMODEL Trial** – Katherine R. Tuttle, Petter Bjornstad, Menno Pruijm, Jeffrey B. Hodgins, David Cherney, Nicolas Belmar, Milenta M. Chacko, Vivek Das, Thomas Idorn, Philip A. Schytz, Matthias Kretzler
- 4:54 p.m. **FR-OR090 Serum Potassium, Hyperkalemia, and the Effect of Hyperkalemia on Treatment Efficacy with Empagliflozin, Finerenone, or Both: A CONFIDENCE Trial Report** – Rajiv Agarwal, Charlie Scott, Johannes F. Mann
- 5:06 p.m. **FR-OR091 Lorundrostat, a Novel Aldosterone Synthase Inhibitor (ASI), in Participants with Uncontrolled Hypertension, CKD, and Albuminuria: Results from Explore-CKD** – Matthew R. Weir, Sarbani Bhaduri, Keung Lee, Oscar G. Galvez, Laura Kooienga, Branko Kopjar, Matthew Novin, David M. Rodman
- 5:18 p.m. **FR-OR092 Impact of Glomerular Filtration Rate and Albuminuria on the Effects of SGLT2 Inhibitors on Kidney Outcomes** – Brendon L. Neuen, Robert A. Fletcher, Vlado Perkovic, Hiddo J.L. Heerspink, SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium (SMART-C)
- 5:30 p.m. **FR-OR093 Global, Regional, and National Burden of CKD in Adults: Updated Systematic Analyses of the Global Burden of Disease Study** – Patrick B. Mark, Lauryn K. Stafford, Morgan Grams, Jennifer S. Lees, Kanyin L. Ong, Josef Coresh, CKD-GBD Collaborators
- 5:42 p.m. **FR-OR094 Community Health Worker Support for Latino Individuals on Dialysis: The Navigate-Kidney Randomized Clinical Trial** – Lilia Cervantes, Kayla Robledo, Michel Chonchol
- 6:00 p.m. Adjourn

### Late-Breaking Research Orals - 3

Grand Ballroom C

Moderators: Krzysztof Kiryluk, MD; Laura H. Mariani, MD, MS, FASN

*Note: Abstracts will be posted online by November 10, 2025.*

- 
- 4:30 p.m. **SA-OR088 Safety and Efficacy of Anti-CD19/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor-Natural Killer Cell (CAR-NK) Therapy in Pediatric Patients with Refractory Systemic Lupus Erythematosus (SLE): A Preliminary Clinical Study** – Hanyan Meng, Chen Zheng, Yi Xie, Qiu-yu Li, Fei Liu, Jingjing Wang, Ming Sun, Enshun Xu, Jianhua Mao
- 4:42 p.m. **SA-OR089 Farabursen Increases Urinary Polycystin-1 and Polycystin-2 and Reduces Height-Adjusted Total Kidney Volume Growth in Patients with ADPKD** – Alan S. Yu, Rekha Garg, Keith A. Bellovich, Arnold L. Silva, Fouad T. Chebib, Claire Padgett, Edmund C. Lee, Tania M. Valencia, Timothy L. Kline, Adriana Gregory, Kevin Carroll, Vishal Patel
- 4:54 p.m. **SA-OR090 Trial to Evaluate and Assess Effects of Comprehensive Kidney Replacement Therapy (KRT)-Directed, Pre-ESKD Education (CoPE) on Home Dialysis Among Veterans (TEACH-VET): Evaluating KRT Decision-Making State (KDS) Outcomes** – Ashutosh M. Shukla, Cydney E. Parmar, I. Magaly Freytes, Yi Guo, Huanguang Jia
- 5:06 p.m. **SA-OR091 Efficacy and Safety of Povecacept in Patients with IgAN and Primary Membranous Nephropathy (pMN) at 48 Weeks of Treatment: The RUBY-3 Study** – James A. Tumlin, Rajesh Yalavarthy, Dong Ki Kim, Ju young Moon, Inwhee Park, Sung Gyun Kim, Sreedhar A. Mandayam, Frank B. Cortazar, Amanda M. Enstrom, Heather Thomas, Jiahua Li, Yih-Chieh Chen, Stanford L. Peng, Jason L. Sanders, Ogo I. Egbuna, Arvind Madan
- 5:18 p.m. **SA-OR092 Long-Term Effect of Oral Methylprednisolone on Kidney Outcomes in Patients with IgAN: TESTING-ON, a Post-Trial Observational Study** – Muh Geot Wong, Jicheng Lv, Yunfei Bao, Rebecca J. Anderson, Dana Kim, Sana Shan, Michelle A. Hladunewich, Vivekanand Jha, Lai Seong Hooi, Helen Monaghan, Vlado Perkovic, Hong Zhang, TESTING Trial Steering Committee
- 5:30 p.m. **AHA/ACC Hypertension Guidelines: What's New for Kidney Diseases?** – Vivek Bhalla, MD, FASN
- 6:00 p.m. Adjourn

## Late-Breaking Research Posters

Exhibit Hall

*Note: Abstracts will be posted online by November 10, 2025.*

- TH-PO1186 Randomized Trial of an Early, Standardized Nephrology Consult Triggered by a Machine Learning Model** – Jay L. Koyner, Aiman Fatima, Ola Anjorin, Matthew M. Churpek, ESTOP Investigators
- TH-PO1187 Preliminary Phase 2 Results of APX-115, a Pan-NOX Inhibitor in Patients with CKD Undergoing Percutaneous Coronary Intervention for Contrast-Induced AKI** – Hyeon-Cheol Gwon, Dae R. Cha, Sung Hwan Moon, Soo Jin Lee, Hyesung Shin
- TH-PO1188 Effect of Polymyxin B Hemoadsorption on Mortality in Patients with Endotoxic Septic Shock: The TIGRIS Trial** – Javier A. Neyra, Matthieu Legrand, George Tomlinson, John A. Kellum, on behalf of the TIGRIS Investigators
- TH-PO1189 Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Evaluating the Efficacy and Safety of HRS-1780 Tablets in Patients with CKD** – Zhihong Liu, Haitao Zhang, Xiaowei Li, Dongwen Zheng, Guangyu Bi, Zi Ye, Xue Dong, Yuehan Wei, Manchen Bao, Gang Cheng, Rong Huang, Qiuli Dong, Shuai Liu
- TH-PO1190 Evidence of Kidney Benefit with HTD1801 in Patients with Mild Renal Impairment** – Filip A. Surmont, Leili Gao, Kui Liu, Alexander Liberman, Leigh Macconell, Meng Yu, Liping Liu, Linong Ji, on behalf of the SYMPHONY Investigators
- TH-PO1191 Comparison of Patients with Primary Hyperoxaluria 1 and Late-Stage CKD from the BONAPH1DE Registry and ILLUMINATE-C Lumasiran Trial** – John C. Lieske, Michelle A. Baum, Efrat Benshalom, Vladimir Belostotsky, Felix Knauf, Anne-Laure A. Sellier-Leclerc, Weiming Du, Mary Callanan, Teresa Kauf, Michael D. Murphy, Jaap Groothoff
- TH-PO1192 Extended-Release Calcifediol (ERC) for Secondary Hyperparathyroidism (SHPT) in Chinese Patients with Stages 3 and 4 CKD: A Phase 3 Trial** – Ming Fang, Haoyan Haoyan, Huijuan Mao, Hong Ren, Hongli Lin, Haiming Li
- TH-PO1193 First-in-Human Study of SK-08, a Novel Soluble Guanylyl Cyclase Activator: Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Potential for CKD** – Ying Du, Hong Zhou
- TH-PO1194 Going with the FLOW: A Large Registry Study on Semaglutide and the Risk of Kidney Complications in Patients with Early Diabetic Kidney Disease** – Genya Aharon-Hananel, Johannes F. Mann, Alona Aharonovich, Efrat Leopold, Gil Chernin
- TH-PO1195 Improving Kidney Failure Risk Predictions for Clinical Trials Across CKD Stages 1-4** – Leonid Shpaner, Panayiotis Petousis, Susanne B. Nicholas, Alex Bui, Obidiugwu Duru, Lindsey M. Kornowske, Cami R. Jones, Kenn B. Daratha, Keith C. Norris, Katherine R. Tuttle, Center for Kidney Disease Research, Education, and Hope (CURE-CKD)
- TH-PO1196 Phase 4, 52-Week, Single-Arm, Post-Marketing Surveillance to Evaluate Safety of Desidustat for Treatment of Anemia in Patients with CKD** – Kevinkumar A. Kansagra, Deven Parmar, Suchi Shah, Prakash Khetan, Hardik K. Shah, Umesh Khanna, Rana G. Singh, Siddharth Mavani

- TH-PO1197 Model-Based Vadadustat Starting Dose Recommendations in Patients with Dialysis-Dependent CKD –**  
Kevin Dykstra, James A. Clary, Pamela C. Navarro Gonzales, Jessica K. Roberts
- TH-PO1198 Vitamin D Metabolome (VDM) Profiles After Single and Repeated Doses of Extended-Release Calcifediol (ERC) in Patients on Hemodialysis (HD) –**  
Charles W. Bishop, John Choe, Akhtar Ashfaq
- TH-PO1199 Efficacy and Safety of MT1013 vs. Etelcalcetide for Secondary Hyperparathyroidism in Patients on Hemodialysis –**  
Linyuan Wang, Ping Zhang, Jianghua Chen, Xiangling Wang, Zhi Yu, Zhian Huang
- TH-PO1200 52-Week Phase 3 Study to Evaluate the Efficacy and Safety of a Novel Iron-Based Phosphate Binder AP301 in Patients on Dialysis with Hyperphosphatemia –**  
Li Zuo, Liangying Gan, Guangyu Bi, Jinsheng Xu, Hong Ye, Huijuan Mao, Hou-yong Dai, Pei Wang, Qing Gao, Yuqing Chen, Yi Li, Jiye Huang, Yan Xu, Hong L. Lin, Aimin Zhong, Jiaxiang Ding, Jing Chen, Yanqing Chi, Hui X. Zheng, Bin Liu, Xiaoliang Zhang, Ming Shi, Yuehong Li, Yingxue C. Liu, Gavin G. Xia
- TH-PO1201 Controlled, Randomized Clinical Trial of Personalized Two-Phase Regional Citrate Anticoagulation in Prolonged Intermittent Kidney Replacement Therapy –**  
Qi Zhang, Xiao Bi, Jun Ma, Jun Xue, Yin Zheng, Chen Yu, Zhuxian Zhu, Jianxin Lu, Leyi Gu, Weiming Zhang, Mingli Zhu, Yining He, Xiaonong Chen, Feng Ding
- TH-PO1202 Reduction in Peritonitis-Related Hospitalization and Catheter Loss with the CloudCath Remote Monitoring System –**  
Don E. Williamson, Eric H. Yu, Aly ElBadry, Glenn M. Chertow
- TH-PO1203 Renal Autologous Cell Therapy in Diabetes and CKD –**  
Bruce F. Culleton, Emily L. Butler, Ahmed Aqeel, Rachita Prakash, Theodore F. Saad, Arnold L. Silva, Thomas D. Wooldridge, Hongxia Yan, Constance M. Barysaukas, Joseph Stavas, Borut Cizman
- TH-PO1204 Joint Effects of Urine Albumin-to-Creatinine Ratio (UACR) and eGFR on Efficacy and Safety with Simultaneous Initiation of Finerenone and an SGLT2 Inhibitor in the CONFIDENCE Trial –**  
Amy K. Mottl, Charlie Scott, Li Li, Rajiv Agarwal
- TH-PO1205 Multimodal Kidney Mechanisms of SGLT2 Inhibition in Patients with Type 1 Diabetes –**  
Ye Ji Choi, Petter Bjornstad, Phoom Narongkiatikhun, Anil K. Karihaloo, Pottumarthi V. Prasad, Luping Li, Kalie L. Tommerdahl, Jeffrey B. Hodgins, Antoine Clarke, Cheril L. Clarkson, Patricia E. Ladd, Daniël H. van Raalte, Hiddo J.L. Heerspink, Nan Hee Kim, Robert G. Nelson, Victor G. Puelles, David Cherney, Laura Pyle, Farid H. Mahmud, Matthias Kretzler
- TH-PO1206 Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Data from VIVIAD, a Phase 2B Randomized Clinical Trial –**  
Michael Karl Schaeffer, Frank T. Weber, Torsten Hoffmann, Christine Wenzkowski, Sylvia Schell-Mader, Antje Meyer, Stefan Tasler, Katharina Fuchs, Kevin Carroll, Tobias B. Huber
- TH-PO1207 Urinary Proteomic Changes Associated with a Healthier Kidney Phenotype After Dapagliflozin Therapy in Adolescent Patients with Type 1 Diabetes –**  
Hailey E. Hampson, Kalie L. Tommerdahl, Farid H. Mahmud, Anil K. Karihaloo, Antoine Clarke, Ye Ji Choi, David Cherney, Hiddo J.L. Heerspink, Phoom Narongkiatikhun, Cheril L. Clarkson, Petter Bjornstad, Laura Pyle
- TH-PO1208 Cardiovascular Risk Prediction Modelling with Semaglutide in Patients with Type 1 Diabetes –**  
Massimo Nardone, Melissa-Rosina Pasqua, Michael A. Tsoukas, Luxcia Kugathasan, Vikas Sridhar, Marcel Musket, David Cherney, Ahmad Haidar

- TH-PO1209 Vertical Sleeve Gastrectomy Reprograms Endothelial, Tubular, and Immune Compartments in Youth-Onset Diabetic Kidney Disease** – [Long Yuan](#), Ye Ji Choi, Abhijit S. Naik, Fadhl Alakwaa, Kristen Nadeau, Kalie L. Tommerdahl, Hailey E. Hampson, Jesse A. Goodrich, Phoom Narongkiatikhun, Daniël H. van Raalte, Laura Pyle, Matthias Kretzler, Petter Bjornstad
- TH-PO1210 Progression of Cardio-Kidney-Metabolic Syndrome in Adolescents with Type 2 Diabetes** – [Laura Pyle](#), Jairo Arturo Pinzon Cortes, Ye Ji Choi, Phoom Narongkiatikhun, Anil K. Karihaloo, Nisha Bansal, Jenny E. Kanter, Karin Bornfeldt, Katherine R. Tuttle, Ian de Boer, Kumar Sharma, Sushrut S. Waikar, Daniël H. van Raalte, Rose Gubitosi-Klug, Kalie L. Tommerdahl, Petter Bjornstad
- TH-PO1211 Effect of Plant-Based Diet on BP and Gut Microbiota in Kidney Transplant Recipients (PLANET-KT)** – [Rungthiwa Kitpermkiat](#), Ekamol Tantisattamo, Sunchai Payungporn, Prapimporn C. Shantavasinkul, Sansanee Thotsiri, Irin Jariyayothin, Surasak Kantachuvesiri, Transplant Coordination Team, the Ramathibodi Excellence Center for Organ Transplantation
- TH-PO1212 Relationship of Albuminuria and Renal Artery Stent Outcomes: Results from the FAIR Randomized Clinical Trial** – [Yuxi Li](#), Fu De Zhou, Beining Wang, Rujie Zheng, Yan Zhang, Jianping Li, FAIR Investigators
- TH-PO1213 PHYOX8: Nedosiran in Pediatric Patients with Primary Hyperoxaluria** – [David J. Sas](#), Sevcan A. Bakkaloglu, Vladimir Belostotsky, María Gema Ariceta Iraola, Gesa Schalk, Loai A. Eid, Jing Yu, Jyoti Arora
- TH-PO1214 Vonafexor in Progressive Alport Syndrome: Early Evidence of Kidney Function Benefit from the ALPESTRIA-1 Trial** – [Bertrand Knebelmann](#), Víctor Martínez Jimenez, Arnold L. Silva, Ankit Mehta, Eric L. Wallace, James F. Simon, Anjay Rastogi, María Vanessa Pérez Gómez, Roser Torra, Suneel M. Udani, Claire Rigother, Moglie Le Quintrec, Myles Wolf, Jacky Vonderscher, Hugo Girma, Pietro Scalfaro
- TH-PO1215 Short-Term Effects of an SGLT2 Inhibitor on Divalent Ions in Patients with ADPKD: The SIDIA Trial** – [Lorena Roth](#), Dusan Harmacek, Thomas Schachtner, Britta George, Cornelia Hofmann, Argyrios D. Georgalis, Reto M. Venzin, Patrick Hofmann, Thomas Fehr
- TH-PO1216 Linking von Hippel-Lindau Disease and SETD2 in a Common Oncogenic Pathway That Converges on the Mitotic Spindle** – [Manga Motrapu](#), Pratim Chowdhury, Sung Yun Jung, Xiaoli Wang, Ashley G. Boice, Ian J. Frew, Ruhee Dere, Dere Lab
- TH-PO1217 Multicenter, Randomized Phase 2 Study Evaluating the Efficacy and Safety of HRS-5965 in Patients with Primary IgAN** – [Jicheng Lv](#), Yan Zha, Shuxin Liu, Dongwen Zheng, Rui Yan, Zengyan Li, Yinan Li, Sheng Qi, Yanfang Zou, Kaiyun Zhang, Chang Shu, Rong Huang, Liuchao Zhang, Hong Zhang
- TH-PO1218 Kidney Function Preservation with Belimumab in Patients with Lupus Nephritis Receiving Mycophenolate Mofetil (MMF) Standard Therapy in the BLISS-LN Trial: Improved Proteinuria, Clinical Outcomes, and Biomarkers for Belimumab vs. Placebo** – [Brad Rovin](#), Hans J. Anders, George Bertias, Ana Delgado, Roger Abramino Levy, Paula S. Curtis, Ciara O'Shea, Ryan Tomlinson, Richard Furie
- TH-PO1219 Patients (Pts) with FSGS Reach Proteinuria <0.7 g/g More Often with Sparsentan (SPAR) vs. Irbesartan (IRB) in DUPLEX: Implications for Kidney Failure (KF) Risk** – [Jai Radhakrishnan](#), Daniel P. Gale, Rasheed A. Gbadegesin, Julia K. Inrig, Radko Komers, Alex Mercer, Edward Murphy, David Pitcher, Moin A. Saleem
- TH-PO1220 Phase 2 Open-Label Trial Evaluating the Efficacy and Safety of Obinutuzumab (OBI) in Treatment of Immunosuppression-Resistant Primary FSGS, or Contraindication to High-Dose Steroids: A Two-Year Study** – [Ladan Zand](#), Eddie L. Greene, Wisit Cheungpasitporn, Maria J. Vargas-Brochero, Sanjeev Sethi, Pierre M. Ronco, Fernando C. Fervenza

- TH-PO1221 Unmasking the Role of Antinephrin Antibodies in FSGS Recurrence After Transplantation: A Multicenter Study from the TANGO Consortium** – [Marie-Camille Lafargue](#), Frank E. Hullekes, Rucháma Verhoeff, Christian Leguern, Paolo Cravedi, Leonardo V. Riella, TANGO Consortium
- TH-PO1222 Acute Dip in eGFR in Patients Treated with Tirzepatide: A Post Hoc Analysis of Long-Term Clinical Trials of Tirzepatide Treatment** – [Bruno Linetzky](#), Adam Stefanski, Irina Jouravskaya, Dachuang Cao, Russell J. Wiese, Ryan Griffin, Imre Pavo, Hiddo J.L. Heerspink
- TH-PO1223 Population Pharmacokinetic and Exposure-Response Modeling Supports BI 764198 20 mg as the Therapeutic Dose for Phase 3, with No Dose Adjustment Required** – [Silke Retlich](#), Hendrik M. Lagraauw, Klas J. Petersson, Undine Falkenhagen, Alexander Voelkner, Nima Soleymanlou, Maximilian T. Lobmeyer, Srinivasa Prasad, Howard Trachtman, Lisa Bungert
- TH-PO1224 Dd-cfDNA Predicts Long-Term Graft Outcomes: Kidney Allograft Outcomes AlloSure Registry (KOAR) Results** – [David Wojciechowski](#), Tarek Alhamad, Dhiren Kumar, Jeffrey A. Klein, Peale Chuang, Edmund Huang, Kalathil K. Sureshkumar, Christopher Lawrence, Renata Ponsirenas, Ling Shen, Robert Woodward, Thin Thin Maw, Alexander C. Wiseman, Daniel C. Brennan, KOAR Principal Investigators
- TH-PO1225 Dapagliflozin Treatment Induces Alternate RAAS Activation in Stable Kidney Transplant Recipients** – [Tarik Shoumariyeh](#), Oliver Helk, Vikas Sridhar, Luxcia Kugathasan, Oliver Domenig, David Cherney, Johannes J. Kovarik, Sunita K. Singh, Chantal M. Kopecky
- TH-PO1226 Molecular Diagnostics to Facilitate Belatacept Monotherapy in Kidney Transplant Recipients** – [David Wojciechowski](#), Cyrus Feizpour, Morgan Marsh, Hwarang S. Han, Swee-Ling Levea, Juan D. Salcedo Betancourt
- TH-PO1227 Potravitug for the Treatment of BK Polyomavirus Infection in Kidney Transplant Recipients: A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial** – [David Wojciechowski](#), Abdolreza Haririan, William S. Asch, Darshana M. Dadhania, Clifton E. Kew, Martha Pavlakis, Kevin J. Fowler, Juergen Beck, Nadiesda Costa
- TH-PO1228 Patient BK Polyomavirus VP1 Genotyping Predicts Neutralizing Antibody Incompatibility and Provides Guardrails for VP1-Targeting Monoclonal Antibody Trial and Therapy** – [Ali Munawar](#), Onno Akkermans, Cristina Úbeda Nicolau, Asanga Bandara, Consuelo Beatriz Correa Sierra, Fernando H. Martins, Steff De Graef, Erin E. Deans, Stephen Ross, Senne Sienaert, Miriam Galindo Cerrada, Vipul C. Chitalia, Nagraj Mani, Stephen D. Weeks
- TH-PO1229 Effects of Sodium-Free Chloride Supplementation on Cardiorenal Function in Chronic Heart Failure** – [Zachary L. Cox](#), Veena Rao, Juan B. Ivey-Miranda, Julieta Moreno Villagómez, Daniela Ramos-Mastache, Jeffrey M. Testani